POST Online Media Lite Edition



 

Eli Lilly & Co. to invest $850m in U.S. operations

Staff Writer |
Eli Lilly and Company announced plans to invest $850 million in its U.S. operations in 2017.

Article continues below






The company's investments span facilities across its U.S. enterprise, including research laboratories, manufacturing sites, and general and administrative areas.

The investments are being driven by demand for Lilly products, as well as its robust pipeline of potential medicines in development targeting cancer, pain, diabetes and other unmet medical needs.

Company leaders were joined by federal, state and local government officials at Lilly Technology Center, where the details of the investments were unveiled, including plans for a new $85 million expansion of its Trulicity (dulaglutide) device assembly operations in the U.S.

This expansion is part of a massive five-year investment by the company to expand its diabetes products manufacturing operations in the U.S., which also includes a $140 million insulin cartridge production facility that was officially dedicated at today's announcement.

David A. Ricks, Lilly's president and chief executive officer, said that Lilly's potential for growth and its long-standing commitment to the U.S. market led to its decision to invest in its U.S. operations and expand its manufacturing footprint in Indianapolis.


What to read next

Eli Lilly to expand Indianapolis R&D headquarters
Court says Eli Lilly may block Teva's generic
Eli Lilly lymphoma drug fails, charge to R&D $30 million